Kyverna Therapeutics, Inc.
KYTXAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Sep 25, 2026 | Needham | $25.00(+258%) | $6.99 | StreetInsider | |
| May 15, 2026 | H.C. Wainwright | Mitchell Kapoor | $25.00(+133%) | $10.74 | TheFly |
| Dec 16, 2025 | Wells Fargo | $33.00(+205%) | $10.81 | TheFly | |
| Dec 15, 2025 | UBS | $32.00(+196%) | $10.81 | TheFly | |
| Dec 15, 2025 | Morgan Stanley | Michael Ulz | $33.00(+205%) | $10.81 | TheFly |
| Dec 4, 2025 | Morgan Stanley | Michael Ulz | $25.00(+221%) | $7.79 | TheFly |
| Oct 27, 2025 | H.C. Wainwright | $20.00(+169%) | $7.44 | TheFly | |
| Aug 29, 2025 | H.C. Wainwright | $10.00(+170%) | $3.71 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Jun 3, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 15, 2026 |
| JP Morgan | maintain | Overweight | May 13, 2026 |
| HC Wainwright & Co. | maintain | Buy | Apr 23, 2026 |
| Wells Fargo | maintain | Overweight | Dec 16, 2025 |
| Morgan Stanley | maintain | Overweight | Dec 4, 2025 |
| Wells Fargo | maintain | Overweight | Oct 30, 2025 |
| HC Wainwright & Co. | maintain | Buy | Oct 27, 2025 |
| Wells Fargo | maintain | Overweight | Oct 8, 2025 |
| HC Wainwright & Co. | maintain | Buy | Aug 29, 2025 |
| HC Wainwright & Co. | upgrade | Neutral →Buy | May 27, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Apr 3, 2025 |
| Morgan Stanley | maintain | Overweight | Apr 1, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Nov 20, 2024 |
| Wells Fargo | maintain | Overweight | Nov 15, 2024 |
| HC Wainwright & Co. | maintain | Neutral | Sep 19, 2024 |
| HC Wainwright & Co. | maintain | Neutral | Aug 15, 2024 |
| JP Morgan | maintain | Overweight | Jul 31, 2024 |
| HC Wainwright & Co. | maintain | Neutral | Jul 16, 2024 |
Earnings History
Next report: Nov 11, 2026 · EPS est. $-0.68| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $-0.63 | $-0.68 | — | — |
| May 12, 2026 | $-0.66 | $-0.75 | — | — |
| Mar 26, 2026 | $-0.80 | $-0.84 | — | — |
| Nov 12, 2025 | $-0.85 | $-0.97 | — | — |
| Aug 12, 2025 | $-0.97 | $-1.00 | — | — |
| May 13, 2025 | $-1.03 | $-1.21 | — | — |
| Mar 27, 2025 | $-0.88 | $-0.87 | — | — |
| Nov 13, 2024 | $-0.80 | $-0.77 | — | — |
News
EMERYVILLE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced that company management will present at the Jefferies Global Healthcare Conference in London, United Kingdom on Thursday, November 19, 2026, at 10:00 am GMT.
Single-dose miv-cel continues to demonstrate promising clinical benefit in progressive multiple sclerosis, achieving robust CAR T-cell penetration in the central nervous system (CNS) and improving disability scores while removing the need for chronic immunotherapies
Did Kyverna Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PR NewswireNEW YORK, Oct. 22, 2026Shareholders are encouraged to contact t
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Miv-cel reversed disability and achieved durable efficacy across all primary and secondary endpoints through one year, with nearly all patients remaining off chronic immunotherapies
Full one-year results from the KYSA-8 registrational trial in stiff person syndrome to be reported, demonstrating sustained clinical benefit and a well-tolerated safety profile with no high-grade CRS or ICANS and no cases of IEC-HS Updated Phase 1 investigator-initiated trial data to be presented, continuing to highlight encouraging clinical activity and a well-tolerated safety profile in progressive multiple sclerosis EMERYVILLE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, …
Kyverna Therapeutics, Inc. (NASDAQ: KYTX - Get Free Report) has received an average rating of "Moderate Buy" from the seven ratings firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to
Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data and Longer-Term Follow-Up for SPS and GMG Trials Transcript
Topline durability data reinforce potential for single-dose miv-cel to free patients from life-long disease burden and chronic immunotherapies, further highlighting miv-cel's differentiated construct
Kyverna Therapeutics, Inc. (KYTX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
EMERYVILLE, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical immunology company pioneering transformative therapies for people with neurologic autoimmune diseases, today announced that company management will present at the following upcoming conferences:
Kyverna Therapeutics, Inc. remains a compelling Buy as it advances mivocabtagene autoleucel for autoimmune diseases, targeting first approval in stiff person syndrome. Updated KYSA-8 trial data show all 26 patients remained off chronic immunotherapies at 16 weeks, with 81% mobility improvement, supporting regulatory momentum. Rolling BLA submission for miv-cel is underway, with anticipated completion in late 2026 and potential approval by mid-2027; key phase 2/3 data in myasthenia gravis expecte…
FDA grants RMAT designation for miv-cel in non-active secondary progressive multiple sclerosis (naSPMS) based on compelling clinical data, further expanding the therapy's potential across neuroimmunology